Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

Francis J. Giles, Gary Guangping Shi, Jorge E. Cortes, Deborah Thomas, Anna R. Keating, Hagop M. Kantarjian, Michael J. Keating, Susan M. O'Brien

Research output: Contribution to journalArticle

Abstract

Purpose: Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy. The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen. Methods: Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL. Patients received FCA (fludarabine 30 mg/m2 i.v. daily for 3 days, cyclophosphamide 300 mg/m2 i.v. daily for 3 days, and amifostine 500 mg i.v. over 15 min daily for 3 days starting 30 min before cyclophosphamide) at intervals of 4-6 weeks for a maximum of six courses. Results: Patients receiving FCA had equivalent rates of sepsis, early death, objective response and survival to those observed in a prior series of 78 patients treated with FC. Amifostine-associated toxicities included nausea, vomiting, and hypotension. Conclusion: The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.

Original languageEnglish (US)
Pages (from-to)223-228
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume52
Issue number3
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Amifostine
B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Toxicity
Chemotherapy
fludarabine
Hypotension
Nausea
Vomiting
Sepsis
Tissue
Drug Therapy
Survival
Infection

Keywords

  • Amifostine
  • Chronic lymphocytic leukemia
  • Cyclophosphamide
  • Fludarabine
  • Sepsis

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. / Giles, Francis J.; Shi, Gary Guangping; Cortes, Jorge E.; Thomas, Deborah; Keating, Anna R.; Kantarjian, Hagop M.; Keating, Michael J.; O'Brien, Susan M.

In: Cancer Chemotherapy and Pharmacology, Vol. 52, No. 3, 01.09.2003, p. 223-228.

Research output: Contribution to journalArticle

Giles, Francis J. ; Shi, Gary Guangping ; Cortes, Jorge E. ; Thomas, Deborah ; Keating, Anna R. ; Kantarjian, Hagop M. ; Keating, Michael J. ; O'Brien, Susan M. / Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. In: Cancer Chemotherapy and Pharmacology. 2003 ; Vol. 52, No. 3. pp. 223-228.
@article{44536854c848493d9c5b06a53383064e,
title = "Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia",
abstract = "Purpose: Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy. The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen. Methods: Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL. Patients received FCA (fludarabine 30 mg/m2 i.v. daily for 3 days, cyclophosphamide 300 mg/m2 i.v. daily for 3 days, and amifostine 500 mg i.v. over 15 min daily for 3 days starting 30 min before cyclophosphamide) at intervals of 4-6 weeks for a maximum of six courses. Results: Patients receiving FCA had equivalent rates of sepsis, early death, objective response and survival to those observed in a prior series of 78 patients treated with FC. Amifostine-associated toxicities included nausea, vomiting, and hypotension. Conclusion: The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.",
keywords = "Amifostine, Chronic lymphocytic leukemia, Cyclophosphamide, Fludarabine, Sepsis",
author = "Giles, {Francis J.} and Shi, {Gary Guangping} and Cortes, {Jorge E.} and Deborah Thomas and Keating, {Anna R.} and Kantarjian, {Hagop M.} and Keating, {Michael J.} and O'Brien, {Susan M.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1007/s00280-003-0654-4",
language = "English (US)",
volume = "52",
pages = "223--228",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

AU - Giles, Francis J.

AU - Shi, Gary Guangping

AU - Cortes, Jorge E.

AU - Thomas, Deborah

AU - Keating, Anna R.

AU - Kantarjian, Hagop M.

AU - Keating, Michael J.

AU - O'Brien, Susan M.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Purpose: Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy. The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen. Methods: Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL. Patients received FCA (fludarabine 30 mg/m2 i.v. daily for 3 days, cyclophosphamide 300 mg/m2 i.v. daily for 3 days, and amifostine 500 mg i.v. over 15 min daily for 3 days starting 30 min before cyclophosphamide) at intervals of 4-6 weeks for a maximum of six courses. Results: Patients receiving FCA had equivalent rates of sepsis, early death, objective response and survival to those observed in a prior series of 78 patients treated with FC. Amifostine-associated toxicities included nausea, vomiting, and hypotension. Conclusion: The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.

AB - Purpose: Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy. The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen. Methods: Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL. Patients received FCA (fludarabine 30 mg/m2 i.v. daily for 3 days, cyclophosphamide 300 mg/m2 i.v. daily for 3 days, and amifostine 500 mg i.v. over 15 min daily for 3 days starting 30 min before cyclophosphamide) at intervals of 4-6 weeks for a maximum of six courses. Results: Patients receiving FCA had equivalent rates of sepsis, early death, objective response and survival to those observed in a prior series of 78 patients treated with FC. Amifostine-associated toxicities included nausea, vomiting, and hypotension. Conclusion: The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.

KW - Amifostine

KW - Chronic lymphocytic leukemia

KW - Cyclophosphamide

KW - Fludarabine

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=0141563716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141563716&partnerID=8YFLogxK

U2 - 10.1007/s00280-003-0654-4

DO - 10.1007/s00280-003-0654-4

M3 - Article

C2 - 12783199

AN - SCOPUS:0141563716

VL - 52

SP - 223

EP - 228

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -